CAPSID & TAIL | In this Q&A interview, Dr. Richard Alm, Alliance Director at CARB-X, shares his insights in how phages are fitting into the antibacterial clinical landscape, and his advice for phage biotech companies developing new drugs to address antibiotic-resistant bacterial infections. CARB-X supports innovative drug development projects in this promising area of research – projects at Eligo Bioscience and Locus Biosciences, and others that will soon be announced. He also looks at the need for product developers to consider the need for rapid effective diagnostics and how CARB-X is supporting R&D in these fields.